Publications | researchideas.co.uk

Publication

How can A&E units improve their performance? (link)

Hospital inspections: lessons to be learnt (link)

Threats to Mankind from Drug Resistant Bacteria and Viruses (link)

Are pharmaceutical mega-mergers in the public interest? (link)

Medical advisory body “NICE” should not spend too much time valuing drugs (link)

Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry (link)

Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease (link)

Pharmaceutical Industry - Innovation is the only way forward (l ink)

Value-based pricing: the wrong medicine for the nation? (link)

Waiting for Decisions on UK Pharmaceutical Pricing (link)

Prevention is better than cure (link)

Health and Social Care Act 2012: Response to Attacks on the Act (link)

Response to Department of Health Consultation on NHS Constitution (link)

Think carefully about value-based drug pricing in the UK and let common sense prevail (link)

The NHS Constitution - the turning point? (link)

Do private patients in the UK help or harm the NHS? (link)

The Pharmaceutical Industry – Friend or Foe? (link)

Response to HM Treasury Consultation on an 'above the line' credit for Research and Development (R&D) (link)

Management Priorities in the NHS under the Health and Social Care Act (link)

A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry (link)

The NHS needs outstanding management as well as a legal framework, for example, to unlock the potential of the property portfolio (link)

Pharmaceutical R & D – the value of radical innovation versus incremental progress (link)

The Health and Social Care Bill: Final Stages in Parliament (link)

Misleading, Biased Reporting on the Health and Social Care Bill in the Media (link)

Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme (link)

The highest standards of medical care urgently require doctors to remain up to date through Continuing Professional Development (link)

What should we expect from medical and pharmaceutical R&D in the future? (link)

The Patent Box (link)

Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011 (link)

Contribution to Debate on UK Pharmaceutical Pricing (link)

Is it possible for NICE to be objective about pharmaceutical pricing? (link)

Research and Development Tax Credits (link)

The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines (link)

NHS Reforms - What the UK Government Policy Changes Really Mean (link)

The UK Needs More Biotechnology Companies (link)

A new value-based approach to the pricing of branded medicines: a consultation (link)

Dept. of Health Consultation on Drug Pricing: “A new value-based approach to the pricing of branded medicines” (link)

Response to HM Treasury Informal Consultation on R&D Tax Credits (link)

The Future of Pharmaceutical R&D (link)

Response to HM Treasury Informal Consultation on the Patent Box (link)

How to encourage pharmaceutical R&D ( link)

Nice Move on Drug Pricing but Where Next? (link)

Liberating the NHS Revisited (link)

NHS Reforms: Health and Social Care Bill 2011 (link)

Which Drugs are the Most Innovative? (link)

NATIONAL HEALTH SERVICE COMMENTS re. Liberating the NHS: Commissioning for Patients (link)

Comments Re. Equity & Excellence: Liberating the NHS (link)

What Women Want: A Manifesto For Health 2010 (link)

Liberating the NHS: Transparency in outcomes- a framework for the NHS (link)

Nature of Publication